GU Cancers 2019 | ProCAID: Investigating the use of AZD5363 alongside chemotherapy in mCRPC

Simon Crabb

Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, discusses results from the Phase II ProCAID trial (NCT02121639), investigating the efficacy of AZD5363 combined with docetaxel in treating metastatic castration-resistant prostate cancer (mCRPC). This interview took place at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video